Compare Stocks: ANIX, RCKT, PRLD, and DMAC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.78 +1.1%	$3.25	$2.32 ▼ $5.46	$96.99M	0.51	361,144 shs	257,663 shs
DMAC DiaMedica Therapeutics	$7.83 +3.6%	$6.74	$5.24 ▼ $10.42	$419.54M	0.98	162,047 shs	209,198 shs
PRLD Prelude Therapeutics	$3.99 -7.4%	$5.03	$1.15 ▼ $6.83	$387.05M	0.97	453,222 shs	1.04 million shs
RCKT Rocket Pharmaceuticals	$2.69 -10.9%	$3.46	$2.53 ▼ $5.45	$367.74M	0.5	1.47 million shs	4.38 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	+1.09%	+0.72%	-24.04%	+1.09%	-19.19%
DMAC DiaMedica Therapeutics	+3.57%	+14.31%	+16.17%	+19.54%	+14.31%
PRLD Prelude Therapeutics	-7.42%	-12.69%	-39.45%	-8.90%	+241.03%
RCKT Rocket Pharmaceuticals	-10.93%	-23.14%	-28.84%	-17.23%	-18.98%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.78 +1.1%	$3.25	$2.32 ▼ $5.46	$96.99M	0.51	361,144 shs	257,663 shs
DMAC DiaMedica Therapeutics	$7.83 +3.6%	$6.74	$5.24 ▼ $10.42	$419.54M	0.98	162,047 shs	209,198 shs
PRLD Prelude Therapeutics	$3.99 -7.4%	$5.03	$1.15 ▼ $6.83	$387.05M	0.97	453,222 shs	1.04 million shs
RCKT Rocket Pharmaceuticals	$2.69 -10.9%	$3.46	$2.53 ▼ $5.45	$367.74M	0.5	1.47 million shs	4.38 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	+1.09%	+0.72%	-24.04%	+1.09%	-19.19%
DMAC DiaMedica Therapeutics	+3.57%	+14.31%	+16.17%	+19.54%	+14.31%
PRLD Prelude Therapeutics	-7.42%	-12.69%	-39.45%	-8.90%	+241.03%
RCKT Rocket Pharmaceuticals	-10.93%	-23.14%	-28.84%	-17.23%	-18.98%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	2.40	Hold	$8.00	187.77% Upside
DMAC DiaMedica Therapeutics	2.60	Moderate Buy	$12.00	53.26% Upside
PRLD Prelude Therapeutics	2.50	Moderate Buy	$8.75	119.30% Upside
RCKT Rocket Pharmaceuticals	2.36	Hold	$8.63	220.63% Upside

Current Analyst Ratings Breakdown

Latest ANIX, RCKT, PRLD, and DMAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	ANIX Anixa Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $6.00
9/17/2026	ANIX Anixa Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/17/2026	PRLD Prelude Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
9/16/2026	RCKT Rocket Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
9/16/2026	RCKT Rocket Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$9.00
9/15/2026	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
9/3/2026	ANIX Anixa Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/1/2026	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
8/19/2026	ANIX Anixa Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	ANIX Anixa Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	460.16	N/A	N/A	$0.38 per share	7.32
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.08 per share	N/A
PRLD Prelude Therapeutics	$12.14M	26.23	N/A	N/A	$1.09 per share	3.66
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$2.56 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$10.93M	-$0.32	N/A	N/A	N/A	N/A	-76.59%	-67.80%	N/A
DMAC DiaMedica Therapeutics	-$32.77M	-$0.72	N/A	N/A	N/A	N/A	-77.76%	-69.43%	11/11/2026 (Estimated)
PRLD Prelude Therapeutics	-$99.50M	-$0.73	N/A	N/A	N/A	N/A	-75.35%	-44.39%	11/11/2026 (Estimated)
RCKT Rocket Pharmaceuticals	-$223.12M	-$0.17	N/A	N/A	N/A	N/A	-52.77%	-44.92%	11/5/2026 (Estimated)

Latest ANIX, RCKT, PRLD, and DMAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/9/2026	Q3 2026	ANIX Anixa Biosciences	-$0.0818	-$0.08	+$0.0018	-$0.08	N/A	N/A
8/11/2026	Q2 2026	PRLD Prelude Therapeutics	-$0.1967	-$0.14	+$0.0567	-$0.14	$5.70 million	$5.70 million
8/10/2026	Q2 2026	DMAC DiaMedica Therapeutics	-$0.2009	-$0.19	+$0.0109	-$0.19	$13.50 million	N/A
8/10/2026	Q2 2026	RCKT Rocket Pharmaceuticals	$0.86	$1.08	+$0.22	$1.08	$0.22 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.55	8.54
DMAC DiaMedica Therapeutics	N/A	6.72	6.72
PRLD Prelude Therapeutics	N/A	4.07	4.07
RCKT Rocket Pharmaceuticals	0.05	9.24	9.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
DMAC DiaMedica Therapeutics	10.12%
PRLD Prelude Therapeutics	79.72%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	26.40%
DMAC DiaMedica Therapeutics	5.00%
PRLD Prelude Therapeutics	49.20%
RCKT Rocket Pharmaceuticals	21.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	4	34.76 million	25.59 million	Optionable
DMAC DiaMedica Therapeutics	35	53.93 million	51.23 million	Optionable
PRLD Prelude Therapeutics	79	79.80 million	40.54 million	Optionable
RCKT Rocket Pharmaceuticals	202	109.78 million	86.39 million	Optionable

ANIX, RCKT, PRLD, and DMAC Headlines

Recent News About These Companies

Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?

September 22 at 8:50 PM | insidermonkey.com

Chardan Capital Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)

September 18, 2026 | theglobeandmail.com

Wedbush Reiterates "Outperform" Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

September 18, 2026 | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Raised to Buy at Needham & Company LLC

September 18, 2026 | americanbankingnews.com

RCKT Aligns With FDA on Completing Phase II Study in Danon Disease

September 16, 2026 | zacks.com

Wedbush Reaffirms Outperform Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

September 16, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded to "Buy" at Needham & Company LLC

September 16, 2026 | marketbeat.com

Martin Wilson Sells 75,364 Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

September 16, 2026 | insidertrades.com

Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Martin Wilson Sells 75,364 Shares of Stock

September 15, 2026 | marketbeat.com

Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Rocket Pharma Shares Climb Premarket After FDA Supports Continuation of Trial

September 15, 2026 | marketscreener.comM

Rocket Pharmaceuticals' (RCKT) "Buy" Rating Reaffirmed at Chardan Capital

September 15, 2026 | marketbeat.com

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

September 15, 2026 | businesswire.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Recommendation of "Hold" from Brokerages

September 15, 2026 | americanbankingnews.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of "Hold" by Analysts

September 15, 2026 | marketbeat.com

Why Rocket Pharmaceuticals, Inc.’s (RCKT) Stock Is Down 5.03%

September 11, 2026 | aaii.comA

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Crosses Below 200-Day Moving Average - Should You Sell?

September 11, 2026 | marketbeat.com

Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?

September 9, 2026 | zacks.com

BlackRock Inc. Invests $33.94 Million in Rocket Pharmaceuticals, Inc. $RCKT

September 2, 2026 | marketbeat.com

Chardan Capital Reiterates "Buy" Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

September 1, 2026 | marketbeat.com

Ieq Capital LLC Invests $1.51 Million in Rocket Pharmaceuticals, Inc. $RCKT

August 27, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANIX, RCKT, PRLD, and DMAC Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$2.78 +0.03 (+1.09%)

As of 09/24/2026 04:00 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

DiaMedica Therapeutics NASDAQ:DMAC

$7.83 +0.27 (+3.57%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$7.88 +0.05 (+0.64%)

As of 09/24/2026 07:30 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Prelude Therapeutics NASDAQ:PRLD

$3.99 -0.32 (-7.42%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$4.00 +0.00 (+0.13%)

As of 09/24/2026 07:30 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.69 -0.33 (-10.93%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$2.73 +0.04 (+1.45%)

As of 09/24/2026 07:59 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANIX, RCKT, PRLD, and DMAC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANIX, RCKT, PRLD, and DMAC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANIX, RCKT, PRLD, and DMAC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANIX, RCKT, PRLD, and DMAC Company Descriptions

Anixa Biosciences NASDAQ:ANIX

DiaMedica Therapeutics NASDAQ:DMAC

Prelude Therapeutics NASDAQ:PRLD

Rocket Pharmaceuticals NASDAQ:RCKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANIX, RCKT, PRLD, and DMAC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANIX, RCKT, PRLD, and DMAC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANIX, RCKT, PRLD, and DMAC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANIX, RCKT, PRLD, and DMAC Company Descriptions

Anixa Biosciences NASDAQ:ANIX

DiaMedica Therapeutics NASDAQ:DMAC

Prelude Therapeutics NASDAQ:PRLD

Rocket Pharmaceuticals NASDAQ:RCKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools